

# Staff Pharmacist-driven Prospective Audit and Feedback at a Community Hospital: Assessing an all Hands on Deck Approach to Antimicrobial Stewardship

Casey J. Dempsey, Pharm.D., BCIDP<sup>1</sup>; Michele Riccardi, Pharm.D.<sup>2</sup>; Kristin E. Linder, Pharm.D., BCPS, BCIDP<sup>1</sup>; Natasha Weiner, Pharm.D.<sup>3</sup>

UNIVERSITY OF SAINT JOSEPH

<sup>1</sup>Hartford HealthCare System, Hartford, CT; <sup>2</sup>University of Saint Joseph School of Pharmacy, West Hartford, CT; <sup>3</sup>MidState Medical Center, Meriden CT

SCHOOL OF PHARMACY

## Introduction

- With increasing rates of antimicrobial resistance, antimicrobial stewardship is at an all-time high the need for effective
- therapy after the antimicrobial has already been initiated The process of prospective audit and feedback is described as a review of antimicrobial therapy accompanied with recommendations to optimize
- Literature describing the successful implementation of antimicrobial stewardship programs often illustrates initiatives and tasks accomplished
- Our study is unique as it describes a successful antimicrobial stewardship pharmacist-driven prospective audit and feedback program program within a small community hospital and our experience with a staff

### Objectives

- completed by staff pharmacists on antibiotic utilization in a community Assess the impact of a prospective audit and feedback program
- training on pharmacist's clinical decision-making skills with providers as a result of the program, and the impact of antimicrobial understanding of the program's impact on daily workflow, engagement Staff pharmacist feedback on the program was assessed to gain a better

of therapy (DOT) for targeted antimicrobials (ciprofloxacin, levofloxacin, Pre- and post-intervention study to assess the primary outcome of days cefepime, ceftazidime, piperacillin/tazobactam)

## Inclusion Criteria

- **Employed by Hartford HealthCare**
- Staff pharmacists at MidState Medical Center who participated in the prospective audit and feedback initiative
- Age ≥18 years old with no upper limit (although there will be a practical limit of approximately 70 based on the two criteria above)
- Willing/able to participate in voluntary survey

- Per-diem pharmacists
- Oncology, anticoagulation, and IV room pharmacists who did not participate in prospective audit and feedback process


# **Endpoints**

# Primary Endpoint

- Days of therapy per 1,000 patient days Antibiotic expenditures
- · Rates of Clostridioides difficile infection (CDI)
- Rates of antimicrobial susceptibility

# Pharmacist Survey of Initiative

- 17 pharmacists are employed at MidState Medical Center. After exclusion of ineligible pharmacists, 11 were surveyed
- Average number of years practicing as a pharmacist: 16.2 years
- Average number of years as a pharmacist at MidState Medical Center: 9.25 years
- 55% of pharmacists reported having no prior antimicrobial stewardship training prior to this initiative
- pathways to help further enhance future antimicrobial therapy assessments Pharmacists requested additional one-on-one training, small in-services, and decision



### Did stewardship training improve pharmacist assessment of antipseudomonal agents? • Yes Did stewardship training improve pharmacist assessment of fluoroquinolones? 73%

### Results

Primary Endpoint	Pre-intervention	Post-intervention	P value
Days of Therapy (DOT/1,000 PDs)			
Piperacillin/tazobactam	29.88	9.25	<0.001
Ceftazidime	8.75	6.47	0.083
Cefepime	20.47	34.35	<0.001
All antipseudomonal agents	62.91	51.67	<0.001
Ciprofloxacin	23.22	9.97	<0.001
Levofloxacin	11.2	5.07	<0.001

Table 2			
Secondary Endpoints	Pre-intervention	Post-intervention	P value
Antimicrobial Expenditures			
Piperacillin/tazobactam	\$52,498	\$10,937	<0.001
Ceftazidime	\$9,952	\$7,457	0.29
Cefepime	\$25,638	\$40,097	0.001
Ciprofloxacin	\$6,700	\$1,954	<0.001
Levofloxacin	\$2,168	\$672	<0.001
Total targeted antimicrobial expenditure	\$95,715	\$62,837	<0.001
Antimicrobial Susceptibility Rate: Pseudomonas aeruginosa			
Piperacillin/tazobactam	84%	89%	0.111
Levofloxacin	67%	72%	0.238
Ciprofloxacin	68%	72%	0.342
Antimicrobial Susceptibility Rate: Escherichia coli			
Piperacillin/tazobactam	89%	93%	<0.001
Cefepime	93%	94%	0.266
Levofloxacin	80%	82%	0.162
Ciprofloxacin	79%	81%	0.170
Clostridioides difficile Infection Rate	4.9/10,000 PDs	2.61/10,000 PDs	0.931

### Discussion

- Implementation of a staff pharmacist-driven prospective authorization observed in cefepime DOT and expenditure feedback program led antipseudomonal drugs used at MidState Medical Center, though increases were piperacillin/tazobactam, ciprofloxacin, levofloxacin, and a significant decrease in overall for DOT ģ a
- Total antimicrobial expenditures significantly decreased post-intervention

• Yes

- Significant increases in Piperacillin/tazobactam susceptibility rates for E. coli was
- A trend towards lower rates of CDI were observed post-intervention
- Staff pharmacists can significantly benefit antimicrobial stewardship initiatives